Short Bowel Syndrome (SBS)

Short Bowel Syndrome (SBS)

Global Short Bowel Syndrome (SBS) Market to Reach $3.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Short Bowel Syndrome (SBS) estimated at US$665.4 Million in the year 2020, is projected to reach a revised size of US$3.7 Billion by 2027, growing at a CAGR of 27.6% over the analysis period 2020-2027. GLP-2, one of the segments analyzed in the report, is projected to record a 29% CAGR and reach US$3 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Growth Hormone segment is readjusted to a revised 26.4% CAGR for the next 7-year period.

The U.S. Market is Estimated at $199.7 Million, While China is Forecast to Grow at 26.8% CAGR

The Short Bowel Syndrome (SBS) market in the U.S. is estimated at US$199.7 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$627.8 Million by the year 2027 trailing a CAGR of 26.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 25% and 23.5% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 19.2% CAGR.

Glutamine Segment to Record 23.6% CAGR

In the global Glutamine segment, USA, Canada, Japan, China and Europe will drive the 23.5% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$19.7 Million in the year 2020 will reach a projected size of US$86.4 Million by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$433 Million by the year 2027.

Select Competitors (Total 42 Featured) -

  • Ardelyx, Inc.
  • Emmaus Life Sciences, Inc.
  • Merck KgaA
  • Naia Pharmaceuticals Inc.
  • Nutrien Ltd.
  • OxThera AB
  • Shire PLC
  • Zealand Pharma A/S
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2020 & 2027
TABLE 4: World Current & Future Analysis for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for GLP-2 by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for GLP-2 by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 7: World Current & Future Analysis for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Growth Hormone by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Growth Hormone by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 10: World Current & Future Analysis for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Glutamine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Glutamine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
TABLE 13: World Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
TABLE 16: USA Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 17: USA Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 18: USA 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
CANADA
TABLE 19: Canada Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 20: Canada Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 21: Canada 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
JAPAN
TABLE 22: Japan Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 23: Japan Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 24: Japan 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
CHINA
TABLE 25: China Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 26: China Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 27: China 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
EUROPE
TABLE 28: Europe Current & Future Analysis for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 29: Europe Historic Review for Short Bowel Syndrome (SBS) by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 30: Europe 15-Year Perspective for Short Bowel Syndrome (SBS) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2020 & 2027
TABLE 31: Europe Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 32: Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 33: Europe 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
FRANCE
TABLE 34: France Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 35: France Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 36: France 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
GERMANY
TABLE 37: Germany Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 38: Germany Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 39: Germany 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
ITALY
TABLE 40: Italy Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 41: Italy Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 42: Italy 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
UNITED KINGDOM
TABLE 43: UK Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 44: UK Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 45: UK 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
REST OF EUROPE
TABLE 46: Rest of Europe Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 47: Rest of Europe Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 48: Rest of Europe 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
ASIA-PACIFIC
TABLE 49: Asia-Pacific Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 50: Asia-Pacific Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 51: Asia-Pacific 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
REST OF WORLD
TABLE 52: Rest of World Current & Future Analysis for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 53: Rest of World Historic Review for Short Bowel Syndrome (SBS) by Drug Class - GLP-2, Growth Hormone, Glutamine and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 54: Rest of World 15-Year Perspective for Short Bowel Syndrome (SBS) by Drug Class - Percentage Breakdown of Value Sales for GLP-2, Growth Hormone, Glutamine and Other Drug Classes for the Years 2012, 2020 & 2027
IV. COMPETITION
Total Companies Profiled: 42

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook